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Abstract 
Naturally occurring antimicrobial cationic polypeptides play a major role in innate and adaptive 
immunity. These polypeptides are found to be either linear and unstructured or structured 
through disulfide bonds. Among the structured antimicrobial polypeptides, defensins comprise 
a family of cysteine-rich cationic polypeptides that contribute significantly to host defense 
against the invasion of microorganisms in animals, humans, insects and plants. Their wide-
spread occurrence in various tissues of these diverse organisms, and their importance in innate 
and adaptive immunity have led to their identification, isolation and characterization. A large 
volume of literature is available on defensins’ occurrence, structural characterization, gene 
expression and regulation under normal and pathological conditions. Much has also been 
published regarding their antimicrobial, antiviral and chemoattractive properties, and their 
molecular and cellular interactions. In this review, we describe the current status of our 
knowledge of defensins with respect to their molecular, cellular and structural biology, their 
role in host defense, future research paradigms and the possibility of their utilization as a new 
class of non-toxic antimicrobial agents and immuno-modulators. 
Keywords: Antimicrobial agent, α- and β-defensin, Peptide disulfide, β-Sheet 
peptide, Immuno-modulator, Membrane permeabilizing agent, Amphiphilic molecule 
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Introduction 
Antimicrobial peptides are widely distributed in nature and represent an ancient mechanism of 
host defense. Among these naturally occurring antibiotic peptides, defensins form a unique 
family of cysteine-rich cationic and structured polypeptides with three or four disulfide bridges. 
Defensins are isolated from mammals, insects, and plants and they serve as effector molecules 
of innate immunity, providing an efficient initial defense against infectious pathogens.1,2 
Mammalian and other vertebrate defensins are quite different from the arthropod defensins in 
their sequence and structure.3,4 Mammalian defensins comprise genetically distinct α- and β-
subfamilies of cationic tri-disulfide peptides. Most defensins appear to be expressed 
constitutively, whereas mediators of inflammation induce the biosynthesis of others.5 
Defensins exhibit remarkable antibacterial, antifungal and antiviral activities against a wide 
variety of microorganisms,1,5 suggesting their role in innate immunity. They also play a major 
role in adaptive immunity.6 It is now becoming clear that defensins constitute a primary 
defense system of the host. The activity of a few α-defensins as specific antagonists of 
adrenocorticotropin has led to their classification as the corticostatin/defensin family.7 This 
review focuses on the current status of defensins in terms of their wide-spread occurrence, 
their molecular, cellular and structural biology, structure–function relationships, mechanism of 
their microbicidal activity and future research paradigms. 
Occurrence, isolation, identification and classification 
Defensins were first identified as a family of peptides in rabbit macrophages and subsequently 
in rabbit, rat, human and guinea-pig neutrophils, and they all belong to the α-defensin sub-
class.2,8 Their primary structures, the sequence homology, the conserved cysteine residues and 
the disulfide linkages of representative α-defensins are provided in Fig. 1. α-Defensins are 
found in neutrophils of humans, rabbits, guinea pigs, rats, macaques and hamsters, in rabbit 
alveolar macrophages and in human and rodent small intestinal Paneth cells.8 β-Defensins were 
originally isolated as a family of 13 homologous peptides in bovine neutrophils.9 The folding of 
the peptide chains and the disulfide motifs (Fig. 2) are distinctly different from α-defensins9 
Subsequently, β-defensins were reported to be expressed in skin, pancreas, kidney, salivary 
glands, prostate, placenta, endocervix, and airway and gingival epithelial cells of 
vertebrates.10,12 α-Defensins consist of 29–35 amino acid residues and are shorter than β-
defensins, consisting of 38–42 residues. α- and β-defensins differ in the location and position of 
the cysteine residues in the amino acid sequence and in their disulfide motifs. Two human β-
defensins, HBD-1 and HBD-2, were structurally characterized and their presence in human skin, 
plasma, saliva, and in the urogenital tract have been identified.12,14 HBD-3 has been identified 
and its expression in adult heart, skeletal muscle, placenta, skin, esophagus, gingival 
keratinocytes, trachea and fetal thymus detected.15 A new and novel HBD-4 has recently been 
identified and its tissue-specific inducible and restricted expression in the testis, uterus, thyroid 
gland, lung and kidney during infection reported.16 
 
Amino acid sequences of α-defensins in human neutrophils (HNP), human intestinal Paneth cells (HD), 
rabbit neutrophils (NP) and rabbit kidney (RK). In HNP sequences, the different amino terminal residue is 
underlined. The conserved disulfide bridges in α-defensins are indicated in HNP-4. The conserved residues 
within a species are bold and underlined.  
 
 Amino acid sequences of β-defensins in human and bovine neutrophils (HBD and BNBD, respectively), 
and two Mediterranean mussel defensins (MGD). The conserved disulfide bridges in β-defensins are 
indicated in HBD-3. The conserved residues in human and bovine neutrophil β-defensins are bold and 
underlined. In Mediterranean mussel defensins, the residues that are not conserved are underlined. The 
disulfide motifs of various defensins are provided in the figure. pE: pyroglutamic acid. 
Several defensins isolated from arthropods have been found to display interesting sequence 
homology to defensins isolated from Mediterranean mussels, even though they belong to 
markedly distinct phylogenetic groups.17 However, these polypeptides differ distinctly (Fig. 2) 
from mammalian and other vertebrate defensins. Though three disulfide bonds generally 
characterize defensins, a few insect defensins with four disulfide bridges have been isolated 
from Mytilus galloprovincialis.17 Defensins isolated from a variety of plants display high 
sequence identity with each other and their amphiphilic β-sheet structure resembles that of 
animal defensins shown in Fig. 3.18 Plant defensins with four disulfide linkages at highly 
conserved locations are designated as γ-thionins. Even though defensins with four disulfide 
bridges have been isolated and characterized from insects and plants, such defensins have not 
yet been identified in vertebrates. Most defensins are primarily linear polypeptides, folded and 
stabilized by three to four disulfide bonds. However, a defensin with the amino and carboxy 
terminals cyclized by a peptide bond has been recently isolated from primate leukocytes.19 
 
A perspective view of the three-dimensional basket-like amphiphilic structure of NP defensin human 
neutrophil-3 deduced from the crystal structure [31]. The side-chains are not included for clarity. The 
yellow color indicates the disulfide bridge. The N- and C-terminal residues form the polar face at the top, 
whereas the middle region assumes the apolar face (the lower portion) of the amphiphilic structure. 
Differences in the sequence and in the folding pattern of mammalian, insect and plant defensins result 
primarily in the alteration of polarity and hydrophobicity of the polar and apolar faces, respectively, 
leading to variation in the amphiphilicity of the structure. This amphiphilicity variation reflects in 
defensins’ diversity in specificity and microbicidal potency. 
Gene expression, regulation and biosynthesis 
Increasing evidence suggests that human α- and β-defensins might descend from a shared 
ancestral gene. The genes encoding HBD-1 and HBD-2 have been assigned to human 
chromosome region 8p23 and 8p22-8p23.1, respectively, close to the α-defensins.12 The 5′-
flanking region of HBD-1 contains nuclear factor (NF)-interleukin (IL)-6 and γ-interferon 
consensus sites, suggesting that inflammatory mediators could regulate its expression.14 The 
cDNA and genomic sequences of the two rabbit macrophage defensins are highly homologous 
and identical to rabbit neutrophil defensins NP1 and NP2, respectively. These genes are closely 
linked within 13 kb, suggesting that they evolved by a recent tandem gene duplication. The 
rabbit macrophage defensin mRNA is found in bone marrow and spleen and organs that 
contain immature polymorphonuclear leukocytes (PMNs).20 While matured PMNs lack defensin 
mRNA, the possibility of a certain degree of mRNA and protein synthesis in activated PMNs has 
not yet been ruled out. 
α-Defensins are produced and stored as pre-propeptides in matured PMNs and Paneth cells. β-
Defensins are constitutively expressed in the epithelial compartment and can be induced to 
higher levels of expression upon infection or inflammation. Metabolic labeling studies in the 
promyelocytic cell line HL-60 and in chronic myeloid leukemia cells indicate that human 
neutrophil pre-prodefensins are processed to mature defensins over 4–24 h via a 75-residue 
prodefensin generated by the cleavage of the signal sequence and a 56-residue prodefensin 
resulting from a subsequent proteolytic cleavage.11 The post-translational and enzymatic 
processing of pre-prodefensins to mature peptides with storage in cytoplasmic granules is a 
specialized feature of granulocytic lineage cells.12 The α-defensins in Paneth cells are also 
synthesized as pre-prodefensins, but they are secreted into the lumen of the small intestine 
where they are proteolytically cleaved into active antimicrobial peptides. The expression of 
human Paneth cell defensins HD-5 and HD-6 is found to be minimal in oral keratinocytes, 
whereas HD-5 mRNA is expressed infrequently and to varying degrees in bronchial and nasal 
epithelial cells.21 The expression of human α- and β-defensin mRNA in gastrointestinal epithelia 
has been found to be tissue- and peptide-specific, and the defensins are expressed with high 
inter-individual variability. Cloning and expression of bovine neutrophil β-defensins indicate 
that the precursor structures of α- and β-defensins are quite different. The structural 
differences of the two defensin families suggest that they could be stored and packaged by 
distinct intracellular pathways and mobilized differently from the respective cells. 
β-Defensins are essentially synthesized in the epithelial compartment with the exception of 
bovine neutrophils. In epithelial cells, HBD genes are found to be both constitutively expressed 
and inducible. Gene expression has been shown to be induced in vitro by stimulation with 
bacterial lipopolysaccharide (LPS) as well as inflammatory mediators. In vivo, up-regulation of 
β-defensin genes has been shown to occur in both infectious and inflammatory states. Gene 
regulation appears to proceed via signal-transduction pathways utilizing NFs including NF-κB 
and NF-IL-6. The amino acid L-isoleucine and several of its analogs can specifically induce 
epithelial β-defensin expression involving the activation of the NF-κB/rel family of trans-
activating factors, suggesting that isoleucine analogs may serve as immuno-stimulants to 
bolster the defense barrier of mucosal surfaces.22 
Characterization and transcriptional profiles of a Drosophila gene encoding an insect defensin 
suggest that insect and mammalian defensins might have evolved independently.23 Though it is 
commonly believed that insect defensin gene expression is only induced upon septic injury and 
infection, the constitutive expression of defensin peptides in insects has recently been 
observed. These results suggest two modes of defense against infection in insects. The first one 
is the transcription of the genes encoding defensin-like peptides, mainly in the fat body after 
septic injury, with a rapid release of the peptides into the hemolymph, and the second mode is 
the constitutive production and storage of the defensin peptides, particularly in hemocytes 
with subsequent release into the hemolymph after immune challenge. 
Plant defensins also form part of the permanent and inducible defense barriers. In plants, both 
small and large cysteine-rich defensin genes are induced through different signal-transduction 
pathways during fruit ripening to protect the reproductive organs against biotic and abiotic 
stress.14 These data suggest that defensins are constitutively and inducibly expressed across the 
phylogenetic spectrum. 
Defensins – key components of innate and adaptive immunity 
The presence of defensins in lower organisms clearly indicates their ancient origins, and argues 
that they developed as a part of a primordial immune protective mechanism. Defensins exhibit 
broad-spectrum antimicrobial activity against bacteria, fungi, mycobacteria and enveloped 
viruses. Constitutive expression of defensins provides a first line of defense against colonization 
by pathogens. Normal gingival epithelial cells express β-defensins, indicating their importance 
in host–pathogen interaction at the oral mucosal barrier and their relevance in oral health. The 
deficiency of neutrophil defensins has been associated with the risk for invasive bacterial 
infections observed in the newborn. Mucoid Pseudomonas aeruginosa, tumor necrosis factor 
(TNF)-α and IL-1β, but not IL-6, induce HBD-2 expression in respiratory epithelia, suggesting the 
protective role of HBD-2 in lung infection caused by mucoid P. aeruginosa. Defensins can also 
activate the classical complement pathway, and they have the potential to modify the 
inflammatory response through the regulation of cytokine production and adhesion-molecule 
expression.24 All these observations suggest a key role for defensins in innate immunity. 
Evidence is accumulating to support the role of defensins in the activation and in the 
recruitment of the cells and machinery of the adaptive immune response. Defensins provide a 
critical link between the innate immune system, which is phylogenetically ancient, and the 
adaptive immune response that is found only in vertebrates. The innate immune system relies 
on germline-encoded receptors on epithelial cells and phagocytes as sentinels of the host–
environment boundary. These pattern-recognition receptors (PRRs) recognize conserved 
pathogen-associated molecular patterns (PAMPs) such as LPS, peptidoglycan, zymosan and 
possibly isoleucine.22 These PRRs initiate an appropriate antimicrobial response to try to 
contain infection, which involves the up-regulation of specific antimicrobial peptides including 
defensins. The second major task for the innate immune system is to activate an appropriate 
adaptive immune response against the invading organism. Recent data suggests that defensins 
may play a key role in the recruitment and activation of the appropriate adaptive effector 
response.25 Examples of the stimulatory effects of defensins on humoral and cell-mediated 
immune elements illustrate this connection.22,25 
Human α-defensins are chemotactic to monocytes, dendritic and T-cells at ∼10−10 M 
concentration, suggesting their importance in shaping the adaptive immune response. β-
Defensins are chemotactic for dendritic and memory T-cells through the chemokine receptor 
CCR6.19 In a murine model, human neutrophil defensins delivered intra-nasally with ovalbumin 
have been shown to enhance the systemic adaptive immune response by increasing antigen-
specific IgG and IgM levels in serum.26 β-Defensin gene expression in vertebrate epithelia, 
including that of humans, and their up-regulation in the presence of bacterial LPS and TNF-α 
emphasize that these molecules might function to protect the host against microbial 
pathogenesis at the critical confrontation sites. These studies provide convincing evidence that 
defensins play a key role in directing and augmenting an adaptive immune response. 
Defensins as antimicrobial and antiviral agents 
Defensins exhibit remarkable antibacterial, antifungal and antiviral activity against a wide 
variety of microorganisms, as established by in vitro studies.2,8 The in vitro minimal inhibitory 
concentrations against a panel of microorganisms range between ∼0.5 and 10 μM for most 
defensin peptides.8 In vitro studies, however, do not mimic the in vivo environment, where 
inflammatory exudates, phagosomes, ions, serum factors and proteases might alter the efficacy 
of these peptides. Hence, the microbicidal efficacy observed for defensins cannot be directly 
related to in vivo applications. However, defensin concentration in vivo might reach significant 
levels at the site of production and secretion (5 μg/10−6 human granulocytes). Neutrophil 
defensin concentration has been elevated by 500–10 000 fold in bronchoalveolar lavage of 
cystic fibrosis (CF) individuals. The concentration of human neutrophil peptide (HNP-1) in the 
saliva of patients with oral diseases and oral inflammation are found to be significantly higher 
than those in healthy subjects.27 The local concentration of defensins has been estimated to be 
in the mg ml−1range in human gingival crevicular fluid. These observations suggest that 
defensins are present in vivo in significant amounts that are likely to have major effects on the 
microbiology of the host. In addition to their high concentration, the microbicidal activity of 
defensins in vivo could be enhanced due to the synergistic interaction with other proteins such 
as lactoferrin and cathelicidins. Defensin and lactoferrin levels are found to be elevated in the 
cerebrospinal fluid of children with meningitis.8 The synergistic action of defensins with other 
host-protective proteins is likely to be relevant in the host–pathogen interaction in vivo. 
Defensins exhibit remarkable antiviral activity against recombinant adeno-associated virus and 
Herpes simplex virus. Direct binding of defensins appears to prevent envelope virus 
infectivity.1,28 
Mechanism of antimicrobial activity 
The antibacterial activity of defensins is generally ascribed to their effects on microbial 
membranes. Defensin-like peptides, being positively charged, interact with negatively charged 
components of microbial membranes that include LPS in Gram-negative bacteria, 
polysaccharides (teichoic acid) in Gram-positive bacteria, and phospholipids (phosphotidyl-
glycerol). Since these membrane components are PAMPs that are not found in mammalian 
cells, defensins in general appear to be electrostatically specific for prokaryotic cells [5]. Human 
defensin HNP-1 has been shown to mediate bactericidal activity against Escherichia coli by 
permeabilizing the outer and inner membranes. An insect defensin with β-sheet structure has 
been reported to permeabilize the cytoplasmic membrane of Micrococcus luteus. Defensins 
in M. luteus cells cause depolarization of cytoplasmic membrane, inhibition of respiration, and 
loss of cytoplasmic potassium and ATP, suggesting that defensins target the bacterial 
cytoplasmic membrane. All research regarding modes of action of antibiotic peptides has been 
carried out with lipid model planar bilayer membranes or small unilamellar vesicles formed 
from lipid mixtures of various compositions of negatively charged to neutral lipids.5,8 These 
studies have led to the hypothesis that in Gram-positive bacteria, the monomeric peptides 
aggregate to form multimeric pores in the cell's single cytoplasmic membrane. In the case of 
Gram-negative bacteria, defensins have to traverse the outer membrane. The high affinity of 
defensins for LPS facilitates competitive displacement of divalent cations (Ca2+ or Mg2+) that 
serve as a bridge between the LPS molecules.29 The initial interaction of defensin with a target 
membrane causes rapid permeabilization of the inner membrane in E. coli. A small defensin-like 
dodecapeptide with a disulfide bridge permeabilizes the outer membrane of P. 
aeruginosa and Salmonella typhimurium and this membrane activity appears to correlate with 
its microbicidal activity. This peptide also interacts with the cytoplasmic membrane of an outer 
membrane-defective mutant E. coli. However, a recent study of cationic antimicrobial peptides 
of varying structures with a planar bilayer and with the cytoplasmic membrane of E. 
coli suggests the possibility that the cytoplasmic membrane is not the target for some or even 
most cationic antimicrobial peptides. Stimulation of autolytic enzymes, interference with 
bacterial DNA and/or protein synthesis, inhibition of DNA synthesis leading to filamentation, or 
binding to and inhibition of cellular nucleic acids have been suggested as the possible 
mechanism of action. Interaction with cellular nucleic acids has been suggested as a credible 
alternative mechanism. Increasing evidence indicates that the antimicrobial mechanism and the 
cytoplasmic target could vary with the primary sequence and the amphiphilicity of the 
antimicrobial peptide.30 
Electrostatic interactions between defensins and the target cell membrane ruling out any 
specific membrane-bound receptor could account for the rare occurrence of resistant bacterial 
strains. However, specific binding sites for plant defensins on fungal cells are required for 
antifungal activity. The resistant strains of S. typhimurium and Staphylococcus aureus have been 
reported to have modified membrane structure involving LPS and teichoic acid, respectively, 
resulting in the neutralization of electrostatic charge, thereby minimizing the interaction with 
defensin peptides. These studies provide convincing evidence that defensins’ initial interaction 
is with the LPS and teichoic acid of Gram-negative and Gram-positive bacteria, respectively. This 
is also consistent with the role of defensins in innate immunity and a possible adjuvant role in 
adaptive immunity. The emergence of resistant strains may have implication directly on the 
antimicrobial activity and/or on the efficacy of defensins to activate the immune system. 
Further research in this direction is required to clarify the function of defensins under these 
circumstances. 
Defensins are expected to be minimally active on host-cell membranes. Their selective toxicity 
is associated with the anionic phospholipid of microbial membranes. In contrast, zwitterionic 
phospholipids and the presence of cholesterol in mammalian cell membranes partly account for 
the minimal cytotoxicity to host cells.8 However, in vitro studies indicate that human defensins 
can have lytic effects on human lymphocytes and endothelial cells as well as murine lymphoid 
cells. The cytolytic mechanism involves an early step of membrane binding, followed by a series 
of cytoskeletal-dependent events that are sensitive to concentration, energy, and temperature. 
The first stage of membrane binding in the defensin-mediated cytotoxicity is inhibited under 
conditions of low temperature and by the presence of serum and heparin.8 The tolerance of 
human erythrocytes, epithelial and endothelial cells to defensins at physiological 
concentrations, temperature, pH and ionic strength has not yet been systematically 
established. These studies would provide invaluable information for defensins’ application in 
pharmaceutical industries. 
Structure–function correlations 
The sequence homology is more than 90% conserved for defensins isolated from a specific 
tissue within a given species. For instance, human neutrophil α-defensin sequences are 
conserved except for one amino acid at the N-terminus. Rabbit neutrophil defensins mostly 
differ only at the C- and N-terminal residues. Similarly, bovine neutrophil β-defensin sequences 
exhibit high sequence homology (Fig. 2). The size and sequence homology of defensins vary to a 
greater extent when compared with those isolated from different biological sources. The 
sequences of human and rabbit neutrophil defensins differ widely (Fig. 1). The minor variations 
within a family of defensins affect significantly their specificity and microbicidal potency. HNP-1 
is a potent antifungal agent against Candida albicans, whereas HNP-3 has minimal activity. 
These two defensins differ only in one amino acid at the N-terminus (Fig. 1). Similarly, HNP-2 is 
significantly less active against C. albicans as compared with HNP-1. The only difference 
between these two molecules is one alanine residue at the N-terminus (Fig. 1). Interestingly, 
human defensins HNP-1 and HNP-2 are equipotent in their cidal activity 
against Capnocytophagaspecies, and their activity is significantly greater than that of HNP-3. 
Similar variations in the bactericidal activity of rat defensins have also been observed. This wide 
functional diversity observed in the family of similarly structured defensins is clearly a 
consequence of minute alterations in sequence, chain length, backbone conformation and side-
chain topography. 
The three-dimensional structures of a few α-defensins reported in the crystalline state and in 
solution4,31 indicate amphiphilic triple-stranded β-sheet structures (Fig. 3). The N- and C-
terminal residues form the polar face, and the middle portion of the sequence constitutes the 
apolar face of the amphiphilic structure (Fig. 3). The polar and apolar faces of the β-sheet 
structure show distinct differences in the amphiphilicity of α-, β-, plant, and insect defensins. 
These variations presumably account for their diversity in specificity and antimicrobial activity. 
The residues at the polar face are found to alter significantly the microbicidal potency and 
specificity of human neutrophil defensins.32 This was demonstrated by the observation that the 
Gram-negative bacteria Actinobacillus actinomycetemcomitans and Porphyromonas 
gingivalis and the Gram-positive bacteria Streptococcus gordonii and Streptococcus mutans are 
insensitive to human neutrophil defensins. However, these same microbes are susceptible to 
rabbit neutrophil defensins that differ significantly from human neutrophil defensins. Analogs 
of human neutrophil defensins incorporating two additional cationic residues at the N- and C-
terminals have been shown to exhibit high microbicidal potency against these organisms, 
suggesting the importance of the N- and C-terminal residues for microbicidal activity. The 
enhanced microbicidal activity observed for defensin analogs could be due to optimization of 
the amphiphilicity of the structure, facilitating specific interactions with microbial 
membranes.32 
The structure of HBD-2 reported previously suggests that its dimeric structure is distinctly 
different from human α-defensins. The higher-order octamer of HBD-2 supports an 
electrostatic charge-based membrane permeabilization mechanism rather than that based on 
formation of bilayer-spanning pores.33 The structure of bovine neutrophil β-defensin has been 
shown to be a triple-stranded β-sheet, the β-bulge preceding the hairpin turn and the 
amphiphilic character. The structural features are consistent with those of other β-defensins. 
The three-dimensional structure of defensins has been used to design simple analogs that 
mimic the structure of native molecules. The constructed analogs have been found to elicit 
microbicidal potency comparable to that of native defensins.34 The microbicidal potency of 
small molecules seem to support the electrostatic charge-based membrane permeabilization 
mechanism. It appears that the amphiphilic structure of defensins stabilized by three or four 
disulfide bridges is critical for membrane permeabilization and antimicrobial activity. 
Defensins and infectious diseases 
In vitro studies suggest that bacterial challenge causes an increase in defensin synthesis and 
secretion by epithelial cells. In vivo studies also indicate elevated defensins concentration in 
plasma, blood, and body fluids from patients with bacterial infection, suggesting defensins’ 
physiological significance in infection. Interestingly, microbial infection does not seem to be a 
problem in the skin disorder, psoriasis. This could be due to the fact that psoriatic epithelium 
up-regulates the expression of a cathelin-class antimicrobial peptide, designated as LL-37, and 
HBD-2 as compared to that of normal skin.5 The synergistic activity of these molecules may 
account for the rare occurrence of infection in this skin disorder.8 
Cystic fibrosis (CF) patients (on the other hand) are highly susceptible to upper-respiratory 
infection by bacterial and fungal pathogens. This is the result of a defective tracheal epithelial 
cell gene product, namely, the CF trans-membrane conductance regulator that causes elevated 
levels of Na+ and Cl− ions in the airway surface fluid. The high cationic concentration associated 
with the airway surface fluid in CF patients appears to inactivate β-defensins, thereby 
enhancing microbial colonization, leading to inflammation and tissue destruction.5,8 It appears 
that only the monovalent and divalent cations inactivate defensins and not the anions. Since 
defensins’ initial interaction with microorganisms involves electrostatic forces, the altered ionic 
environment might compromise the initial interaction of defensins with microbial membranes. 
Periodontitis is one of the most common chronic infectious diseases of humans and is a major 
cause of tooth loss. This oral disease is strongly associated with the formation of a 
predominantly Gram-negative anaerobic biofilm in the gingival crevice or periodontal pocket. P. 
gingivalis and A. actinomycetemcomitans are the most well-documented periodontal 
pathogens having multiple virulence factors that could circumvent normal host-defense 
mechanisms. In healthy individuals, the secretion of β-defensins from oral epithelium and the 
constant influx of neutrophil α-defensins along with other salivary defense molecules serve as 
an efficient barrier against the formation of a pathogenic sub-gingival plaque or biofilm. The 
disruption of this barrier can lead to the progression of periodontal disease. P. gingivalis uses a 
mechanism known as chemokine paralysis to inhibit the expression of IL-8 by gingival epithelial 
cells, which may indirectly decrease the defensin barrier by inhibiting neutrophil emigration.35 
Bacterial DNA can also down-regulate the production of human defensins in epithelial cells. 
Moreover, studies have demonstrated that P. gingivalis can survive the non-oxidative killing 
mechanisms of PMNs, which may be of greater importance in the anaerobic environment of the 
periodontal pocket. This finding may be in part due to the lack of microbicidal activity of human 
neutrophil α-defensins against oral pathogens including P. gingivalis and A. 
actinomycetemcomitans.32 
Another mechanism that may be very important in the host–pathogen interaction, particularly 
in the periodontium, is the direct deactivation or clearance of defensins by substances such as 
dermatan sulfate and α 2-Macroglobulin. Approximately 60% of the glycosaminoglycan content 
of healthy human gingiva is made of dermatan sulfate, which has recently been shown to bind 
to defensins and completely neutralize their microbicidal activity.36 Similarly, defensin levels 
may be decreased by activated α 2-macroglobulin. α 2-Macroglobulin is the major serum 
protease inhibitor, which upon activation, will bind to defensin peptide.37 In the environment of 
the periodontal pocket, bacterial tissue invasion and high levels of protease activity could cause 
increased levels of activated α 2-macroglobulin. The defensin–α 2-macroglobulin interaction 
may constitute an important mechanism in the host–pathogen interaction that warrants 
further investigation. 
Additional regulatory functions 
Human α-defensins inhibit fibrinolysis by modulating tissue-type plasminogen activator and 
plasminogen binding to fibrin and endothelial cells, which could have significant implications in 
thrombotic pathology. In pathological conditions, defensins released in the circulation might 
adhere to the endothelium and their presence in the vascular tissues could contribute to the 
pathological consequences of inflammation. In vitro studies have shown that neutrophil 
defensins interact with ACTH receptors, inhibiting ACTH-induced steroidogenesis. neutrophil 
defensins induce histamine secretion from mast cells mediated by a G-protein-dependent 
response, which is distinctly different from antigen-IgE-mediated activation.8 α-Defensins are 
found to induce proteoglycan-dependent catabolism of low-density lipoprotein (LDL) by 
vascular cells, leading to a new class of inflammatory apolipoprotein, suggesting that they could 
possibly contribute to atherogenesis.8 They also regulate secretory leukocyte protease inhibitor 
and elafin release from bronchial epithelial cells, indicating their role in the dynamic regulation 
of the antiprotease secretion in the lung at the site of inflammation. Defensins increase 
proliferation of epithelial cells, suggesting their involvement in wound healing.38 These 
important biological functions establish that defensins are multifunctional cell-effector 
molecules in addition to their role in integrating the innate and adaptive immune responses. 
Future paradigms and summary 
Increasing evidence unambiguously establishes that defensins play a major role in adaptive and 
innate immunity. However, less research has been focused on the pharmaceutical application 
of defensins as an alternative to circumvent microbial adaptive resistance and toxicity 
associated with conventional antibiotics. Though defensins have been suggested as therapeutic 
agents for several infectious diseases, the development has been hampered by difficulties and 
the expenses involved in their large-scale production. However, large-scale synthesis of human 
neutrophil defensins and their analogs has recently been reported.32 Recombinant technology 
for the production of defensins is yet to emerge, though there are a few reports that describe 
the synthesis of small amounts of defensins. Interestingly, it has been demonstrated that 
defensin gene transformation and its expression impart disease resistance in plants, which is 
equivalent to the conventional fumigation practice. Similar research in humans will be 
invaluable to control or prevent infectious and inflammatory diseases. The toxicity of naturally 
occurring defensins to human cells at physiological conditions has to be thoroughly examined 
for pharmaceutical applications. 
The studies on the structural biology of defensins have identified simple amphiphilic molecules 
that mimic the structure of defensins and elicit similar antimicrobial potency.34 Peptide 
detergents can be generated by alteration of amphiphilicity of these simple molecules. These 
detergents could selectively lyse microbial membranes and target infectious pathogens. As 
mentioned earlier, high ionic strength of the airway fluid associated with CF leads to the 
impairment of β-defensins’ activity. However, a cyclic defensin, wherein amino and carboxy 
terminals are cyclized by a peptide bond, has been reported to be active even at high ionic 
strength.19 This suggests a novel approach to overcome the salt-sensitive deactivation of 
defensins in CF patients. Research should focus on this class of cyclic defensins for 
pharmaceutical applications when the natural defense barrier is compromised in a pathological 
state. Structure–function studies could identify the functional domain for defensins’ 
chemotactic activity to monocytes and other adaptive immune cells. Such studies might 
facilitate the design and synthesis of simple molecules that could activate or direct the adaptive 
immune response, and serve as immuno-modulators. 
The interaction between activated α 2-macroglobulin and defensin peptides is an undeveloped 
area that warrants further investigation. With the observations that α 2-macroglobulin 
functions as an extra-cellular chaperone as well as a major serum protease inhibitor, the 
interplay between defensins and α 2-macroglobulin becomes more intriguing. Defensins appear 
to be recycled in vivo by activated α 2-macroglobulin via receptor-mediated endocytosis. 
Recycling may occur through either the LDL receptor-related protein, or CD91, the heat shock 
protein receptor. Since CD91 plays a role in antigen presentation, and α 2-macroglobulin acts as 
a T-cell adjuvant, one could speculate that defensins might aid in the delivery of non-self 
lipoprotein or glycolipid antigens and help direct the adaptive immune response accordingly. 
Further research in this area might clarify the precise role of α 2-macroglobulin in the activity of 
defensins. 
In summary, this review has attempted to describe the current status of defensins as natural 
barriers at the host–microbe interface, linking adaptive and innate immunity. The current 
knowledge of defensins envisages the possibility of their utilization as a new class of natural 
antibiotics to overcome microbial adaptive resistance to existing conventional antibiotics. They 
might serve as immuno-modulators to activate the immune system suppressed by infection and 
inflammation. 
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